Should I buy or sell Champions Oncology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks .

What is Champions Oncology's stock price target for 2024?

2 equities research analysts have issued 1 year price objectives for Champions Oncology's stock. Their CSBR share price targets range from $7.50 to $7.50. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 48.1% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts .

Are investors shorting Champions Oncology?

Champions Oncology saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 58,100 shares, a decrease of 7.2% from the March 15th total of 62,600 shares. Based on an average daily trading volume, of 7,000 shares, the days-to-cover ratio is presently 8.3 days. Currently, 1.0% of the company's stock are sold short. View Champions Oncology's Short Interest .

When is Champions Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast .

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported ($0.19) earnings per share for the quarter. The biotechnology company earned $12.02 million during the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%.

What is Ronnie Morris' approval rating as Champions Oncology's CEO?

8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com . Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Champions Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD) , Intel (INTC) , Cytosorbents (CTSO) , Micron Technology (MU) , Corbus Pharmaceuticals (CRBP) , NVIDIA (NVDA) , AbbVie (ABBV) , Agile Therapeutics (AGRX) , CRISPR Therapeutics (CRSP) and Exelixis (EXEL) .

NASDAQ:CSBR

Champions Oncology (CSBR) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free CSBR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $5.07
▼
$5.10
50-Day Range: $9.11
▼
$10.96
52-Week Range: $7.19
▼
$14.68

Volume: 1,206 shs
Average Volume: 2,908 shs
Market Capitalization: $68.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Get Champions Oncology alerts:

Champions Oncology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 48.1% Upside
$7.50 Price Target
Short Interest: Healthy
0.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 1.04
Based on 25 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

230th out of 919 stocks

Biological Products, Except Diagnostic Industry

31st out of 148 stocks

3.3

Analyst's Opinion

Consensus Rating
Champions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Champions Oncology has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.95% of the float of Champions Oncology has been sold short.
Short Interest Ratio / Days to Cover
Champions Oncology has a short interest ratio ("days to cover") of 8.3.
Change versus previous month
Short interest in Champions Oncology has recently decreased by 7.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Champions Oncology does not currently pay a dividend.
Dividend Growth
Champions Oncology does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Champions Oncology has received a 71.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Champions Oncology is -0.81.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 25 news articles for Champions Oncology this week, compared to 11 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Champions Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Champions Oncology is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Champions Oncology is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Champions Oncology has a P/B Ratio of 14.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Champions Oncology Stock (NASDAQ:CSBR)

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CSBR Stock News Headlines

April 18, 2024 | msn.com

How to beat Manchester City, Jude bellingham reveals after Champions League triumph

April 18, 2024 | msn.com

Champions League talking points: Are PSG a team now? Was Xavi wrong?

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 18, 2024 | sports.yahoo.com

Champions League semi-final schedule revealed

April 18, 2024 | msn.com

Bayern Munich’s Champions League win over Arsenal offers club, coach Thomas Tuchel and striker Harry Kane redemption arc

April 18, 2024 | apnews.com

PSG star Tabitha Chawinga of Malawi overcomes obstacles en route to Champions League success

April 18, 2024 | msn.com

Champions League rules leave teams chasing a moving target in the Bundesliga

April 18, 2024 | theguardian.com

Champions League team of the week: Kimmich breaks record … and Arsenal

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | finance.yahoo.com

Will Champions Oncology (NASDAQ:CSBR) Spend Its Cash Wisely?

April 15, 2024 | reuters.com

Terzic seeks Dortmund reaction in Champions League return against Atletico

April 15, 2024 | msn.com

Champions League final 2024: When and where the match is and how to watch it on TV

April 15, 2024 | msn.com

Which Premier League teams can qualify for the 2024-25 Champions League, Europa, or Conference Leagues?

April 15, 2024 | msn.com

Champions Tower Defense Codes For April 2024

April 13, 2024 | msn.com

Pep Guardiola’s $1.26m watch makes headlines after Champions League match

April 13, 2024 | msn.com

Harlequins reach Champions Cup semi-finals with nail-biting win over Bordeaux

April 13, 2024 | sports.yahoo.com

Bayern Munich suffer Kingsley Coman injury blow before Arsenal Champions League decider

April 13, 2024 | msn.com

Leinster banish Champions Cup ghosts as La Rochelle’s three-peat dream emphatically ended

April 13, 2024 | msn.com

Tottenham see Champions League hopes dented and Brentford finally end winless run

April 13, 2024 | msn.com

Investec Champions Cup: Leinster 40-13 La Rochelle - Five-try Leinster knock out holders La Rochelle

April 12, 2024 | msn.com

Masters 2024: Tom Watson killed jovial vibe at Champions Dinner with a single question

April 12, 2024 | msn.com

Hopes of fifth Champions League spot dented

April 12, 2024 | msn.com

Investec Champions Cup: Leinster make two changes for La Rochelle quarter-final

April 12, 2024 | finance.yahoo.com

Genpact's CEO BK Kalra Joins Catalyst CEO Champions For Change

April 12, 2024 | msn.com

Why Premier League is now at risk of missing out on fifth Champions League spot

April 12, 2024 | msn.com

The race for fifth Champions League place: Tottenham blow as Premier League lose ground

April 12, 2024 | msn.com

Here's what's on Jon Rahm's menu at the annual Masters Champions Dinner

See More Headlines

Receive CSBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Fiscal Year End: 4/30/2024
Next Earnings (Estimated): 7/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CSBR
CUSIP: N/A
CIK: 771856
Web: www.championsoncology.com
Phone: (201) 808-8400
Fax: 410-369-0390
Employees: 143
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $7.50
Low Stock Price Target: $7.50
Potential Upside/Downside: +48.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,340,000.00
Net Margins: -19.76%
Pretax Margin: -19.62%
Return on Equity: -850.72%
Return on Assets: -32.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.60
Quick Ratio: 0.60

Sales & Book Value

Annual Sales: $53.87 million
Price / Sales: 1.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 14.90

Miscellaneous

Outstanding Shares: 13,590,000
Free Float: 7,383,000
Market Cap: $68.83 million
Optionable: Optionable
Beta: 0.39

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Ronnie Morris
President Chief Executive Officer & Director
David Barry Miller
Chief Financial Officer
Karin Abarca Heidemann
Vice President-Scientific Operations
Michael Ritchie
Chief Commercial Officer
Maria Mancini
Vice President-Pharmacology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CSBR Stock Analysis - Frequently Asked Questions

Should I buy or sell Champions Oncology stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CSBR shares.
View CSBR analyst ratings or view top-rated stocks.
What is Champions Oncology's stock price target for 2024?: 2 equities research analysts have issued 1 year price objectives for Champions Oncology's stock. Their CSBR share price targets range from $7.50 to $7.50. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 48.1% from the stock's current price.
View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts.
Are investors shorting Champions Oncology?: Champions Oncology saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 58,100 shares, a decrease of 7.2% from the March 15th total of 62,600 shares. Based on an average daily trading volume, of 7,000 shares, the days-to-cover ratio is presently 8.3 days. Currently, 1.0% of the company's stock are sold short.
View Champions Oncology's Short Interest.
When is Champions Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024.
View our CSBR earnings forecast.

How were Champions Oncology's earnings last quarter?: Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported ($0.19) earnings per share for the quarter. The biotechnology company earned $12.02 million during the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%.
What is Ronnie Morris' approval rating as Champions Oncology's CEO?: 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Champions Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL).

This page (NASDAQ:CSBR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Champions Oncology (CSBR) Stock Price, News & Analysis

Champions Oncology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Champions Oncology Stock (NASDAQ:CSBR)

CSBR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CSBR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™